Jason Goolsby, DO
Family Medicine · Brownsville, TNNPI 1801925938
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (59.2%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 39 manufacturers reported payments, led by AbbVie at 48.1% of the total. Reporting peaked in 2021 at $11,502 and has fallen 65.0% since, to $4,027 in 2025. Among family medicine clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 851 payments — averaging $43.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$18K
- Johnson & Johnson$6K
- AstraZeneca$2K
- Biogen$1K
- Novo Nordisk$1K
- Boehringer Ingelheim$1K
- plus $8K from 33 others
What the payments were for
- Consulting fees$1,2883%
- Speaking & faculty fees$21,96359%
- Travel & lodging$4711%
- Food & beverage$13,30936%
- Education$470%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$37,077 in reported general payments places this provider in the 95th percentile of 2,087 family medicine providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SkyclarysOmaveloxolone | 11 | $151,884 |
| EliquisApixaban | 138 | $137,551 |
| FarxigaDapagliflozin Propanediol | 144 | $131,162 |
| JardianceEmpagliflozin | 163 | $128,224 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 123 | $95,144 |
| MounjaroTirzepatide | 73 | $85,678 |
| OzempicSemaglutide | 66 | $80,853 |
| XareltoRivaroxaban | 54 | $47,484 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 56 | $45,001 |
| TrulicityDulaglutide | 31 | $43,720 |
| EntrestoSacubitril/Valsartan | 52 | $43,103 |
| LinzessLinaclotide | 55 | $42,887 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 40 | $33,252 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 23 | $28,844 |
| GlyxambiEmpagliflozin/Linagliptin | 31 | $28,645 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Glyxambi, Synjardy Xr | $1,216 | $178,430219 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $1,535 | $164,415184 claims |
| BiogenSkyclarys | $1,436 | $151,88411 claims |
| PfizerEliquis | $718 | $137,551138 claims |
| Novo NordiskOzempic, Xultophy 100-3.6, Rybelsus | $1,288 | $133,084106 claims |
| Lilly USA, LLCMounjaro, Trulicity | $758 | $129,398104 claims |
| GSKTrelegy Ellipta | $865 | $95,144123 claims |
| Johnson & JohnsonXarelto, Invokamet | $5,872 | $54,24066 claims |
| MerckJanumet Xr, Januvia, Belsomra | $429 | $51,37476 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $482 | $45,00156 claims |
| NovartisEntresto | $187 | $43,10352 claims |
| AbbVieLinzess | $17,825 | $42,88755 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,087 family medicine providers in Tennessee.
Other family medicine in Brownsville
- Kevin DennisFranklin$354K
- Charolette JacksonBartlett$162K
- Keren HolmesNashville$58K
- Kabir Harricharan SinghNewport$49K
- Khaisha GistAntioch$49K
- Jerry PunchKnoxville$45K
- Christopher HollowayAntioch$41K
- Curtis JantziKingsport$39K
- Ellen ClelandChattanooga$38K
- Meredith SchweitzerAntioch$37K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.